Organization | Trium Analysis Online GmbH

Trium Analysis Online GmbH Report issue

For profit Phase 2 Phase 3

Founded: Munich Germany (1999)

Organization Overview

First Clinical Trial

2011

NCT01336530

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Trium Analysis Online GmbH

Active Ingredients

Drugs in Phase 3 Trials (8)

aluminum hydroxide (Gaviscon) (1 trial)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (2 trials)

magnesium hydroxide (1 trial)

oxaliplatin (eloxatin) (2 trials)

Oxetacaine (1 trial)

pertuzumab (perjeta) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (5)

aflibercept (zaltrap) (1 trial)

leucovorin (1 trial)

paclitaxel (taxol) (1 trial)

ramucirumab (cyramza) (2 trials)

tipiracil (lonsurf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Esophagitis (Phase 3)

Stomach Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 13